Pfizer Income Taxes 2010-2023 | PFE
Pfizer annual/quarterly income taxes history and growth rate from 2010 to 2023. Income taxes can be defined as the total amount of income tax expense for the given period.
- Pfizer income taxes for the quarter ending December 31, 2023 were $-0.795B, a 445.65% decline year-over-year.
- Pfizer income taxes for the twelve months ending December 31, 2023 were $-1.115B, a 133.5% decline year-over-year.
- Pfizer annual income taxes for 2023 were $-1.115B, a 133.5% decline from 2022.
- Pfizer annual income taxes for 2022 were $3.328B, a 79.7% increase from 2021.
- Pfizer annual income taxes for 2021 were $1.852B, a 400.54% increase from 2020.
Pfizer Annual Income Taxes
(Millions of US $) |
| 2023 |
$-1,115 |
| 2022 |
$3,328 |
| 2021 |
$1,852 |
| 2020 |
$370 |
| 2019 |
$583 |
| 2018 |
$-266 |
| 2017 |
$-9,049 |
| 2016 |
$1,123 |
| 2015 |
$1,990 |
| 2014 |
$3,120 |
| 2013 |
$4,306 |
| 2012 |
$2,221 |
| 2011 |
$3,621 |
| 2010 |
$1,153 |
| 2009 |
$2,145 |
Pfizer Quarterly Income Taxes
(Millions of US $) |
| 2023-12-31 |
$-795 |
| 2023-09-30 |
$-964 |
| 2023-06-30 |
$-71 |
| 2023-03-31 |
$715 |
| 2022-12-31 |
$230 |
| 2022-09-30 |
$356 |
| 2022-06-30 |
$1,570 |
| 2022-03-31 |
$1,172 |
| 2021-12-31 |
$249 |
| 2021-09-30 |
$-328 |
| 2021-06-30 |
$1,123 |
| 2021-03-31 |
$808 |
| 2020-12-31 |
$-64 |
| 2020-09-30 |
$-347 |
| 2020-06-30 |
$422 |
| 2020-03-31 |
$359 |
| 2019-12-31 |
$-1,982 |
| 2019-09-30 |
$3,047 |
| 2019-06-30 |
$-915 |
| 2019-03-31 |
$433 |
| 2018-12-31 |
$-1,536 |
| 2018-09-30 |
$66 |
| 2018-06-30 |
$648 |
| 2018-03-31 |
$556 |
| 2017-12-31 |
$-11,336 |
| 2017-09-30 |
$727 |
| 2017-06-30 |
$739 |
| 2017-03-31 |
$821 |
| 2016-12-31 |
$14 |
| 2016-09-30 |
$249 |
| 2016-06-30 |
$347 |
| 2016-03-31 |
$513 |
| 2015-12-31 |
$-188 |
| 2015-09-30 |
$567 |
| 2015-06-30 |
$905 |
| 2015-03-31 |
$706 |
| 2014-12-31 |
$545 |
| 2014-09-30 |
$911 |
| 2014-06-30 |
$1,082 |
| 2014-03-31 |
$582 |
| 2013-12-31 |
$430 |
| 2013-09-30 |
$985 |
| 2013-06-30 |
$1,782 |
| 2013-03-31 |
$1,109 |
| 2012-12-31 |
$513 |
| 2012-09-30 |
$-183 |
| 2012-06-30 |
$1,180 |
| 2012-03-31 |
$711 |
| 2011-12-31 |
$434 |
| 2011-09-30 |
$1,216 |
| 2011-06-30 |
$1,077 |
| 2011-03-31 |
$894 |
| 2010-12-31 |
$-2,012 |
| 2010-09-30 |
$558 |
| 2010-06-30 |
$1,472 |
| 2010-03-31 |
$1,135 |
| 2009-12-31 |
$-807 |
| 2009-09-30 |
$1,092 |
| 2009-06-30 |
$786 |
| 2009-03-31 |
$1,074 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$148.755B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
